---
title: "Jade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288672622.md"
description: "Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The company intends to use the funds for clinical trials, R&D, and general corporate purposes. Underwriters include Jefferies, TD Cowen, and UBS. The offering is expected to close on June 5, 2026. Following the announcement, Jade's stock declined, closing Wednesday at $17.59 and trading down 7.02% in overnight markets."
datetime: "2026-06-04T06:05:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288672622.md)
  - [en](https://longbridge.com/en/news/288672622.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288672622.md)
---

# Jade Biosciences Prices $150 Mln Offering Of Shares At $15.00/shr; Stock Down

(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company, priced a public offering of 10 million shares at $15.00 per share. The gross proceeds to Jade from the offering are expected to be $150.0 million.

Jade's lead investigational candidate, JADE101, is being evaluated in a Phase 2 clinical trial for the treatment of immunoglobulin A nephropathy.

The offering is expected to close on June 5, 2026, subject to approval conditions.

In addition, Jade has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock at the public offering price, less underwriting discounts and commissions.

Jade intends to use the net proceeds from this offering, together with its existing cash and equivalents, to fund clinical trials, preclinical studies, and manufacturing in support of its programs, as well as for additional research and development activities, capital expenditures, working capital and other general corporate purposes.

Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers for the offering.

JBIO has traded between $6.57 and $28.00 over the last year. The stock closed Wednesday's trade at $17.59, down 0.90%.

JBIO is currently down 7.02% at $16.35 in the overnight market.

For More Such Biotech Stock News, visit rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [JBIO.US](https://longbridge.com/en/quote/JBIO.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Jade Bios prices $150M follow-on offering, 10M shares at $15; nets ~$140.3M](https://longbridge.com/en/news/288775020.md)
- [Jade reports interim Phase I results of JADE101 for IgAN](https://longbridge.com/en/news/288395063.md)
- [BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD.  | BGMS Stock News](https://longbridge.com/en/news/288767239.md)
- [The IPO Buzz: Parabilis Therapeutics (PBLS Proposed) Upsizes IPO by 1/3 to $600 Million](https://longbridge.com/en/news/289210583.md)
- [A Look At Belite Bio (BLTE) Valuation After Recent Share Price Weakness](https://longbridge.com/en/news/289062484.md)